Advanced Prostate Cancer: From Bench to Bedside: 2nd Edition

Dear Colleagues,

Prostate cancer is generally viewed as a slow-growing unaggressive cancer, yet it is one of the most commonly diagnosed cancers and a leading cause of morbidity and mortality in men around the world. Over the last few years, the management of advanced prostate cancer has evolved tremendously, leading to new therapeutic options that have helped to improve survival and quality of life. All of this success is due to intensive research that has moved from preclinical models through the phases of clinical research to the currently available treatment options. This Special Issue will cover these presently available treatments and consider how best to use these therapeutic options in advanced/metastatic castration-sensitive and castration-resistant prostate cancer. This Special Issue will address ongoing basic and clinical research that may lead to new therapies, as well as how to better use the options that we have at our disposal in terms of timing, combination, and sequencing. This Special Issue will also consider the exponential growth of molecular imaging and radioligand therapy over the past few years. Understanding how this will fit into the diagnostic and therapeutic landscape of advanced prostate cancer is a priority. Importantly, works that integrate predictive, prognostic, and genomic biomarkers are critically important to the optimal use of available therapeutics and help us to develop new effective options for the future.

Prof. Dr. Fred Saad
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.